Published by Josh White on 5th April 2023
(Sharecast News) - Life sciences company Avacta Group announced that it had dosed the first patient in the fifth cohort of the first-in-human phase one trial of its innovative oncology drug 'AVA6000' on Wednesday.
URL: http://www.digitallook.com/dl/news/story/33418619/...